HR+/HER2- Advanced Breast Cancer Clinical Trials

14 clinical trials for HR+/HER2- Advanced Breast Cancer across international registries, including 4 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• ORION-1: Study of AVZO-023 as a Single Agent and in Combination With AVZO-021, and/or Endocrine Therapy in Advanced Solid Tumors — RECRUITING · PHASE1
• Study of AVZO-021 in Patients With Advanced Solid Tumors — RECRUITING · PHASE1
• A Study of Invikafusp Alfa (STAR0602), a Selective T Cell Receptor (TCR)-Targeting, Bifunctional Antibody-fusion Molecule, in Combination With Sacituzumab Govitecan in Participants With Advanced Solid Tumors — RECRUITING · PHASE1
• Chidamide/Everolimus for PIK3CA Wild-type/Mutant HR+/HER2- Advanced Breast Cancer — RECRUITING · PHASE2
• A Phase IIIB study to evaluate the use of capivasertib in combination with fulvestrant in patients with HR+ / HER2- advanced breast cancer who have relapsed/progressed on ET and CDK4/6 inhibitor reflecting Real World Clinical Practice in Spain: CAPItana Study. — TERMINATED · PHASE3
• Exploration of Dalpiciclib + Chidamide in HR+/HER2- Advanced Breast Cancer After Failure of CDK4/6 Inhibitor: a Phase Ⅰb Study — COMPLETED · PHASE1
• A Study of SH3765 Tablets in Combination With Fulvestrant in Patients With HR+/HER2- Advanced Breast Cancer. — ACTIVE_NOT_RECRUITING · PHASE1
• A Prospective Non-interventional Study to Evaluate Clinical Outcomes of Ribociclib Combined With Endocrine Therapy in Elderly Patients With HR+HER2 - Advanced Breast Cancer in Routine Clinical Practice in Russian Federation — ACTIVE_NOT_RECRUITING
• An interventional, open-label, phase III study to evaluate the safety, efficacy, and impact on quality of life of capivasertib alongside standard-of-care endocrine treatment in patients with HR+/HER2- advanced breast cancer and progression on prior endocrine-based treatment (CAPIcorn) — TERMINATED · PHASE3
• A Prospective NIS to Evaluate the Clinical Outcomes of Risarg® (Ribociclib) Combined With Endocrine Therapy or Chemotherapy in Patients With HR+HER2 - aBC in Routine Clinical Practice in the Russia — ACTIVE_NOT_RECRUITING
• A Real-World Study in Patients With HR+/HER2- Advanced Breast Cancer — WITHDRAWN
• Exploration of Dalpiciclib Plus HDACi in HR+/HER2- Advanced Breast Cancer After Failure of CDK4/6 Inhibitor — NOT_YET_RECRUITING · PHASE2
• Real-world Study of Sacituzumab Govitecan Monotherapy or Combination Therapy in Recurrent or Metastatic HER2-negative Breast Cancer — ACTIVE_NOT_RECRUITING
• Albumin-bound Paclitaxel、Dalpiciclib and AI in ER-Low (1%-10%) HER2-ABC — NOT_YET_RECRUITING · NA

Refine this search